CNR Institutional Research Information System

Martelli, Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.640
NA - Nord America 1.104
SA - Sud America 312
EU - Europa 279
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.364
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.064
SG - Singapore 763
CN - Cina 317
BR - Brasile 265
HK - Hong Kong 191
VN - Vietnam 160
FR - Francia 99
IT - Italia 68
KR - Corea 64
IN - India 35
BD - Bangladesh 23
NL - Olanda 20
AR - Argentina 19
FI - Finlandia 18
JP - Giappone 17
GB - Regno Unito 16
CA - Canada 15
ID - Indonesia 14
IQ - Iraq 12
MX - Messico 12
DE - Germania 11
MA - Marocco 11
IL - Israele 8
ES - Italia 7
ZA - Sudafrica 7
SA - Arabia Saudita 6
CL - Cile 5
CO - Colombia 5
EC - Ecuador 5
PE - Perù 5
PY - Paraguay 5
RS - Serbia 5
UA - Ucraina 5
JM - Giamaica 4
AT - Austria 3
EG - Egitto 3
KE - Kenya 3
LT - Lituania 3
NP - Nepal 3
PK - Pakistan 3
RU - Federazione Russa 3
SE - Svezia 3
TR - Turchia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
IE - Irlanda 2
IS - Islanda 2
JO - Giordania 2
MY - Malesia 2
OM - Oman 2
TH - Thailandia 2
TW - Taiwan 2
UZ - Uzbekistan 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BY - Bielorussia 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PL - Polonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.364
Salva come PNG Salva come JPEG
Città #
Santa Clara 555
Singapore 425
Hong Kong 190
Hefei 136
San Jose 107
Lauterbourg 91
Ashburn 90
Seoul 63
Ho Chi Minh City 54
Hanoi 39
Beijing 38
Los Angeles 30
Buffalo 29
New York 29
Helsinki 17
Dallas 16
Orem 14
Chennai 11
São Paulo 11
Belo Horizonte 9
Tokyo 9
Minamishinagawa 8
Rio de Janeiro 8
Haiphong 7
Bengaluru 6
Biên Hòa 6
Da Nang 6
Phoenix 6
Rome 6
Salvador 6
Baghdad 5
Houston 5
Quito 5
Shanghai 5
Atlanta 4
Belgrade 4
Brasília 4
Denver 4
Falkenstein 4
Guarulhos 4
Jakarta 4
Johannesburg 4
Manchester 4
Mexico City 4
Milan 4
Montreal 4
Ninh Bình 4
Quảng Ngãi 4
Thái Bình 4
Toronto 4
Bologna 3
Brooklyn 3
Buenos Aires 3
Hải Dương 3
London 3
Montevideo 3
Pietragalla 3
Porto Alegre 3
Rio Grande 3
Riyadh 3
San Francisco 3
Santo André 3
Stockholm 3
São José dos Campos 3
The Dalles 3
Vinh 3
Amman 2
Basra 2
Blumenau 2
Bogotá 2
Braço do Norte 2
Bắc Ninh 2
Bến Tre 2
Cairo 2
Cape Town 2
Catania 2
Colombo 2
Elk Grove Village 2
Erbil 2
Frankfurt am Main 2
Guadalajara 2
Hangzhou 2
Helena 2
Hortolândia 2
Huế 2
Ibiúna 2
Irecê 2
Istanbul 2
Jacobina 2
Jeddah 2
João Pessoa 2
Juiz de Fora 2
Kingston 2
Kyiv 2
Louisville 2
Ludhiana 2
Madrid 2
Marrakesh 2
Marília 2
Medellín 2
Totale 2.222
Salva come PNG Salva come JPEG
Nome #
Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts, 71
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 68
The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH 68
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. 66
Strutture di dati: livelli di astrazione e metodi di definizione come strumento di progetto dei programmi 66
TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors 64
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 60
Inositide signaling in the nucleus: from physiology to pathology. 59
The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. 58
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. 54
Nuclear inositides: facts and perspectives, 51
Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy 50
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. 45
Nuclear phosphoinositides and their roles in cell biology and disease. 44
The emerging multiple roles of nuclear Akt. 43
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?, 41
Morphological and biochemical patterns in skeletal muscle apoptosis. 40
Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. 40
Activity of the selective I?B kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. 38
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway, 37
Effects of ectopic expression of NGAL on doxorubicin sensitivity 36
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy 36
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 36
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy 36
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 36
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia. 36
Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. 35
Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells, 35
PKC-zeta expression is lower in osteoblasts from arthritic patients: IL1-beta and TNF-alpha induce a similar decrease in non-arthritic human osteoblasts. 35
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. 35
Rabphilin Localizes with the Cell Actin Cytoskeleton and Stimulates Association of Granules with F-actin Cross-linked by {alpha}-Actinin, 35
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 35
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. 34
Targeting the cancer initiating cell: The ultimate target for cancer therapy 34
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 34
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. 33
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. 33
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. 32
Caspase-9 is the upstream caspase activated by 8-methoxypsoralen and ultraviolet-A radiation treatment of Jurkat T leukemia cells and normal T lymphocytes, 32
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 31
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. 31
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. 31
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 31
Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry, 31
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. 31
Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. 31
Quantitative immunodetection of key elements of polyphosphoinositide signal transduction in osteoblasts from arthritic patients shows a direct correlation with cell proliferation, 31
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. 30
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors 30
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. 30
Significance of nuclear phospholipase C signaling through type 1 IGF receptor, 29
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute 28
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukaemia, 28
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health 28
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. 28
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. 28
Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology 27
Nuclear inositide signaling in myelodysplastic syndromes. 27
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast 27
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 27
Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts, 27
Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias, 27
Nuclear Phospholipase C {beta}1 (PLC{beta}1) Affects CD24 Expression in Murine Erythroleukemia Cells, 27
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways 27
TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest. 26
Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells. 26
Molecular mechanisms for pituitary thyrotroph cell growth, 25
Synergistic proapoptotic activity of recombinant trail plus the Akt inhibitor perifosine in acute myelogenous leukemia cells 25
Significance of subnuclear localization of key players of inositol lipid cycle, 25
PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. 25
Signal transduction within the nucleus: revisiting phosphoinositide inositide-specific phospholipase Cbeta1, 25
Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway, 24
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients, 24
Targeting prostate cancer based on signal transduction and cell cycle pathways. 24
Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks. 24
Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. 24
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. 24
Nuclear diacylglycerol kinase teta activated in response to nerve growth factor stimulation of PC12 24
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. 24
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 23
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. 23
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulation of PC12 cells, 23
Antiapoptotic role of p38 mitogen activated protein kinase in Jurkat T cells and normal human T lymphocytes treated with 8-methoxypsoralen and ultraviolet-A radiation, 23
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells, 23
Nuclear phosphoinositide specific phospholipase C (PI-PLC)-ss1: a central intermediary in nuclear lipid-dependent signal transduction, 22
Flow cytometric detection of total and serine 473 phosphorylated Akt, 22
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. 22
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. 22
Nuclear diacylglycerol Kinase-..... in C2C12: subnuclear localization and possible involvement in DNA replication myogenic differentiation, 22
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes. 21
Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation, 21
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. 21
Nuclear phospholipase C beta1 and cellular differentiation. 21
Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. 20
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. 20
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. 19
Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid 19
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways, 19
Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia 19
Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells. 19
Totale 3.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.763
article - articoli 10.330
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.093
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20241 0 0 0 0 0 0 0 0 0 0 0 1
2024/20251.423 9 5 86 66 530 42 33 20 10 21 329 272
2025/20261.946 79 142 147 402 371 72 329 130 85 101 88 0
Totale 3.370